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STEM CELLS: AN OVERVIEW OF THERAPEUTIC APPROACHES 
CHELSEE J. BRUBAKER 
ABSTRACT 
 The complexity of life exhibited in humans and other living creatures has drawn 
many to investigate the principles associated with organismal growth and development. A 
few broad questions: How do tissues develop into specified organs? How are these 
tissues maintained? Do they become different tissues? Scientific research has incessantly 
been seeking answers to these as well as a plethora of other questions. While on a quest 
to better understand developmental biology, investigators discovered unique populations 
of stem cells within a variety of tissues, which retain both varying degrees of 
developmental plasticity and their potential for self-regeneration. This thesis provides a 
brief review discussing the development and history of stem cells in medicine and 
associated research on these cells and their potential clinical applications.  
Substantial attention has been paid to pluripotent embryonic stem cells (ESC) and 
induced pluripotent stem cells (iPSC) which are able to be recapitulate ESC properties 
through the in vitro reprogramming of somatic cells. While, the ethical and legal issues 
have greatly hindered the use of ESCs this has made the benefit of iPSCs so great. An 
interconnected network of pluripotency-associated genes, integrates external signals and 
exerts control to maintain the state of pluripotency. Recent research has proven the 
pluripotency regulatory network to be flexible such that the underlying principles 
promise unprecedented opportunities for scientific study and regenerative 
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medicine. Additional topics reviewed here include vast clinical applications of stem cells 
as well as their notable limitations. 
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INTRODUCTION 
Stem cells have captivated the attention of the scientific research community and 
medical professionals for several decades. The biotechnology and pharmaceutical 
industries have taken every opportunity to investigate these cells considering their 
immense potential to benefit biological understanding and medicine. Since origination of 
the term “stem cells” in the late 19th century numerous studies have confirmed and 
defined this uniquely complex cell type (Ramalho-Santos & Willenbring, 2007). Stem 
cells have been universally defined as cells capable of indefinite proliferation or self-
renewal as well as the ability to produce differentiated or specialized cells. 
Differentiation means a daughter cell can either remain a stem cell, which is functionally 
identical to the parent cell (“undifferentiated”), or become a committed progenitor which 
includes specialized functions like that of further differentiated cell types. Therefore, 
differentiation is a one-way process of developing a specialized cell such that the initial 
cell becomes increasingly and irreversibly committed to its fate (Gurdon & Melton, 
2008). 
 
Hematopoietic Stem Cells 
James Till and Ernest McCulloch conducted early stem cell research using the 
hematopoietic (blood-forming) system as a model due to ease of accessibility 
(McCulloch & Till, 1960). This pair of scientists lethally irradiated the bone marrow of 
mice and transplanted marrow cells of normal mice. Survival of the irradiated mouse 
would completely depend on a component in bone marrow of normal mice that is capable 
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of reconstituting the entire blood system. Transplants were successful thus confirming the 
presence of the hematopoietic stem cell (HSC) and its ability to multiply and differentiate 
into multiple lineages. Stem cells develop within a complex environment which includes 
a dynamic relationship with a variety of signals and interactions within its niche. 
Continued investigation and advances in research technologies have allowed the study of 
hematopoietic stem cells and led to these cells being one of the most well characterized 
stem cell populations of the mammalian system (Challen et al., 2009).  
 
The identification and purification of HSCs by unique cell surface molecule 
expression has been made possible by advances in flow cytometric technology. 
Currently, HSCs cannot be determined by any single marker. However, a variety of 
strategies have been developed to achieve the desired result of producing the highest 
yield of long-term, multi-lineage reconstituting HSCs. Multi-parameter flow cytometry 
protocols have made it possible to easily identify and purify HSCs based on combinations 
of cell surface markers (Mayle, Luo, Jeong, and Goodell, 2013). Table 1 presents a 
summary of cell surface phenotypes and the hematopoietic cell types they enrich. 
Although cell phenotyping can be informative, HSCs are ultimately defined by their 
functional capacity in a stem cell-ablated host which is determined by their ability to 
repopulate the bone marrow and generate the major blood lineages (Mayle, Luo, Jeong, 
and Goodell, 2013). The phenotype of stem cells has been well documented to change 
developmentally therefore, phenotype alone cannot be relied upon to definitively identify 
stem cells (Mayle, Luo, Jeong, and Goodell, 2013). 
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Table 1. Cell Surface Phenotypes.  Technical advances in research technologies prove 
remarkable improvement of purification of the easily accessible hematopoietic stem cell 
and progenitor cell populations. Various laboratories have developed specific selection 
strategies using the known cell surface phenotypes to identify and compare HSCs and 
expected side populations. Image from (Mayle, Luo, Jeong, and Goodell, 2013).  
 
 
Adequate purification of HSCs has allowed increased investigation of the 
molecular mechanisms involved in hematopoietic differentiation including cell 
interactions, and regulatory mechanisms that are relevant to human disease (Till & 
McCulloch, 1980). The well-defined hematopoietic system has helped to make stem cell 
biology and stages of differentiation of other systems increasingly clear. In addition to 
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flow cytometry technology, significant advances in cell culture technology and the 
definition of defined media additives, cytokines and morphogenetic factors to direct 
cellular differentiation has increased the understanding of regulatory mechanisms that 
drive differentiation. Extensive research has been conducted to determine the regulatory 
steps of stem cell differentiation or commitment. At this step stem cells lose their 
multipotent ability and independence as they irrevocably enter specific lineage 
differentiation (Till & McCulloch, 1980).  
  
Embryonic Stem Cells 
Embryonic stem cells (ESC) are the most superior stem cell, having the greatest potential 
for clinical applications. Researchers Martin Evans and Matthew Kaufman successfully 
isolated mouse ESCs and published their work in the peer-reviewed scientific journal 
Nature in 1981. The text described isolation of the pre-implantation blastocyst which is a 
hollow sphere of cells that give rise to the placenta and the inner cell mass (ICM) 
containing embryo (Evans & Kaufman, 1981). Cells from the ICM are pluripotent as they 
have the capacity to differentiate and form the majority of differentiated cell types from 
the three germ layers: the ectoderm, endoderm and mesoderm (Figure 1). These 
pluripotent cells are relatively short-lived in the embryo in vivo because upon 
implantation they differentiate and become transient as they lack self-renewing capacity. 
However, this state of pluripotency can be maintained indefinitely in culture in an 
undifferentiated state, with specific conditions and various growth factors (Rippon & 
Bishop, 2004). A variety of ESC lines are available to date as this advancement has 
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encouraged the development of genome manipulation technology that has resulted in 
‘knock out’ and ‘knock in’ transgenic animals for the investigation of gene expression 
and regulation in vivo (Thomas & Capecchi, 1987). 
 
Figure 1. Zygote Development & in vivo Pluripotent Ground State. Mouse ESCs 
were successfully isolated by harvesting the pre-implantation blastocyst. This hollow 
sphere of cells gives rise to the placenta and the inner cell mass (ICM) containing 
embryo. Pluripotent cells having the capacity to differentiate and form the majority of 
differentiated cell types from the three germ layers: the ectoderm, endoderm and 
mesoderm are isolated from the ICM. These cells are limited to in vivo pluripotency as 
they differentiate and become transient as they lack self-renewing capacity after 
implantation. Image from (Hackett & Surani, 2014). 
 
 
 
Despite the many benefits of ESCs, generation of human ESCs has had 
considerable controversy. Legislation governing the use of human embryos has been 
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Despite the many benefits of ESCs, generation of human ESCs has had 
considerable controversy. Legislation governing the use of human embryos has been 
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modified several times to address ethical concerns and strong objections to destruction of 
human embryos for scientific research. According to the National Institutes of Health 
(NIH), which is a steward of medical and behavioral research for the United States, has 
set the current grant policy statement for the use of ESCs (U. S. Dept. of HHS). The 
mission of the NIH is to seek fundamental knowledge about the nature and behavior of 
living systems and the application of that knowledge to enhance health, lengthen life, and 
reduce illness and disability. Additionally, the NIH seeks to ensure integrity and 
accountability in its grant award and administration processes by relying on a system of 
checks and balances and separation of responsibilities within its own staff. Strict 
guidelines limit the use of stem cells for research and the derivation of stem cells from 
human embryos is prohibited in any NIH funded research (U. S. Dept. of HHS). 
Developmental biologist John Gurdon extensively investigated the possibility of 
reprogramming of somatic cells by nuclear transplantation of nuclei from differentiated 
cells into an enucleated egg in frogs (Gurdon, 1962). Gurdon harvested and inserted 
mature and differentiated intestinal epithelial cell nucleus into enucleated eggs. This 
resulted in an embryo and eventually an adult frog. This was definitive proof that even a 
differentiated single intestinal epithelial cell contains all genetic material required to 
make an entire organism and its various cell types (Gurdon, 1962). Gurdon concluded 
that single cell nucleus contains all the genetic information for organisms to develop. 
This was the first experimental discovery suggesting mature cells have the potential to be 
converted to stem cells by nuclear reprogramming (Gurdon & Melton, 2008). Therefore, 
a switch in gene expression of one kind of cell to that of another unrelated cell type is 
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defined as nuclear reprogramming. Consequently, stem cells can also be further defined 
to reflect their developmental potential (Table 2) (Jaenisch & Youg, 2008). 
Reprogramming of somatic cells has been achieved by nuclear transplantation of a 
somatic nucleus into an enucleated egg and most recently by introducing defined 
transcription factors into somatic cells (Jaenisch & Youg, 2008).   
 
Table 2. Stem Cells & Development Potential. Customary classification of functional 
stem cells according to their developmental potential. Image from (Jaenisch & Youg, 
2008). 	
	
 A variety of methods have been investigated in an attempt to reprogram somatic 
cells to an induced pluripotent state which essentially functions like an embryonic stem 
cell. Thus, the possibility to derive one kind of specialized cell (lung tissue) from another, 
more accessible, tissue (skin) in the same individual. Nuclear reprogramming is of great 
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medical interest as it has the potential to generate inexhaustible patient-specific cells in 
addition to a variety of other scientific advancements. The ground or naïve state of 
pluripotency is said to be a stable state and can be maintained by modulating several 
independent extrinsic signaling pathways (Figure 2) (Hackett & Surani, 2014). This so-
called blank slate state liberates cells from any epigenetic constraints which confirms 
unbiased developmental potential (Hackett & Surani, 2014). Therefore, initially 
unrestricted cells are subject to various pathway signals to reinforce or antagonize naïve 
pluripotency, which initiates cellular lineage commitment (Nichols & Smith, 2009).  
Consequently, a significant amount of research has been dedicated to recapitulating naïve 
pluripotency such as a stable cell line like that of ESCs, while avoiding use of the human 
blastocyst.  
 
Figure 2. Naïve Pluripotency Reinforced or Antagonized. Reprogramming somatic 
cells to an induced pluripotent state which essentially functions like an embryonic stem 
cell has been widely investigated. The stable or blank state of pluripotency eliminates 
epigenetic constraints on cells. As such, cells are initially unrestricted and have been 
confirmed to be developmentally unbiased. The ground or naïve state which can be 
maintained by modulating several independent extrinsic signaling. Therefore, cells are 
subject to various pathway signals which aim to reinforce or antagonize naïve 
pluripotency, thus initiating cellular lineage commitment. Image from (Hackett & Surani, 
2014). 
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More specifically, researchers Kazutoshi Takahashi and Shinya Yamanaka 
investigated the possibility of capturing naïve pluripotency in vitro by reprogramming 
differentiated cells by overexpressing ESC-specific transcription factors in ESC culture 
conditions. The investigators successfully reprogrammed adult fibroblast to produce 
induced pluripotent stem cells (iPSC), essentially an uncommitted state (Takahashi & 
Yamanaka, 2006).  This technology aims to avoid ethical hurdles associated with the use 
of human embryos as well as issues concerning rejection following transplantation in 
patients. It was hypothesized that the factors that maintain ESC identity would also be 
important to induction of pluripotency of somatic cells. Therefore, the two scientists 
investigated 24 genes as possible candidates for factors that would induce pluripotency in 
somatic cells (Table 3) (Kadarmideen, 2016). 
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Table 3. Yamanaka Investigates 24 Genes. World-renowned researchers Kazutoshi 
Takahashi and Shinya Yamanaka investigated 24 genes associated with ESC identity and 
known signaling pathways. The scientists hoped to capture naïve pluripotency in vitro by 
reprogramming differentiated cells by overexpressing ESC-specific transcription factors 
in ESC culture conditions. The possible candidate factors were said to induce 
pluripotency in somatic cells which would seek to evaded ethical issues associated with 
the use of human embryos in addition to other benefits. Meticulous interrogation of the 
highly expressed genes were systematically eliminated to reveal the Yamanaka factors 
(Oct3/4, Sox2, Klf4, c-Myc). These four genes critically regulate the developmental 
signaling network necessary to maintain the pluripotency of ESCs.  Image from 
(Kadarmideen, 2016). 
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 Upon examining the effect of withdraw of individual factors, the Yamanaka 
factors (Oct3/4, Sox2, Klf4, c-Myc) were revealed and published in the peer-reviewed 
scientific journal Cell in 2006. These are highly expressed genes in ESCs, and their over-
expression can induce pluripotency in both mouse and human somatic cells. Thus, 
indicating that these four genes critically regulate the developmental signaling network 
necessary to maintain the pluripotency of ESCs and probably also to induce pluripotent 
stem cells (Takahashi & Yamanaka, 2006). Histological analyses of teratomas confirmed 
the resulting iPSCs are able to differentiate in vitro as well as in vivo into all germ layers. 
The final demonstration was the ability of iPSCs to contribute to mouse chimeras and all 
iPSC mice in tetraploid complementation studies. This research demonstrated that the 
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four selected transcription factors could induce pluripotent cells from adult mouse 
fibroblast cultures. Recent developments in the field include non-viral gene transfer 
which limits the potential genotoxic effects associated with retroviral transfection, yet the 
efficiency is significantly lower (Kumar, Anand, and Kues, 2016).  Therefore, 
advancements in technology and the widespread basic and clinical implications of iPSCs 
continue to drive stem cell research forward.   
 
iPSC Research and Clinical Uses  
Stem cells are at the core of scientific research as investigators seek to answer the most 
intriguing questions in biology and medicine today (Ramalho-Santos & Willenbring, 
2007). The pluripotent features of iPSCs are a promising tool for developing a better 
understanding of both the molecular nature of the state of pluripotency and the 
progression of disease, disorders or injury (Trounson & McDonald, 2015). Figure 3 
displays the scientific scheme used by researchers to derive human iPSCs. Domestic 
animal studies allow researchers an incredibly beneficial comparative model of chronic 
diseases and cancer (Kumar, Anand, and Kues, 2016). A wide variety of medical and 
scientific advantages are possible with modern stem cell research including development 
of novel cell therapies. Additionally, iPSCs represent a basic tool for individual in vitro 
interrogation of potentially beneficial pharmaceutical therapies as well as safety prior to 
clinical testing (Ahfeldt, Litterman, and Rubin, 2017). Therefore, research constantly 
aims to investigate the molecular mechanisms of reprogramming based on the regulatory 
circuitry of the pluripotent state.  
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Figure 3. Derivation of Human iPSCs. A wide variety of research aiming to investigate 
questions of medicine and biology includes iPSCs. Disease, disorders or injury are 
increasingly becoming more understood at the molecular level of diagnosis, progression 
and treatment because of iPSCs. This basic image represents a simple schematic 
approach used by all scientific research utilizing human iPSCs. Image from (Kumar, 
Anand, and Kues, 2016). 
 
 
Reprogramming Somatic Cells 
Nuclear reprogramming studies have furthered scientific understanding of the process of 
cell differentiation and maintenance of gene expression (Gurdon & Melton, 2008). 
Additionally, autologous cell therapies are possible which allows an individual’s 
defective cells to be replaced by normal cells, either of the same type or a different type 
(Hochedlinger & Jaenisch, 2003). With continued research scientists hope to one day be 
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able to derive complete organs with this technology (Kobayashi, Yamaguchi, Hamanaka, 
Kato-Itoh, Yamazaki, Ibata, Sato, Lee, Usui, Knisely, Hirabayashi, and Nakauchi, 2010). 
As such, a heart or a pancreas that is genetically identical to an individual has the 
potential to be transplanted and immunosuppression therapy can be completely avoided 
(Gurdon & Melton, 2008; Wang, Dumont, and Rudnicki, 2014). Currently, researchers 
have demonstrated human iPSCs that were efficiently differentiated to cardiac progenitor 
cells were able to reduce remodeling of the heart after ischemic damage (Carpenter et al., 
2012). Furthermore, nuclear reprogramming allows development of disease-specific 
culture lines to be maintained for further investigation (Gurdon & Melton, 2008).   
 
Figure 4. Derivation of Human iPSCs: Research and Clinical Opportunities. Modern 
iPSC research including development of novel cell therapies boasts possibilities of a wide 
variety of medical and scientific advantages. Additionally, research aims to investigate 
questions of medicine and biology includes such that nuclear reprogramming studies 
have revealed greater understanding of the cell differentiation process and maintenance 
of gene expression. This information has been applied to a variety of applications in 
which iPSCs are being used to research health issues and their potential to impact clinical 
medicine. Image from (Kumar, Anand, and Kues, 2016).   
	 15	
	
 
 
 
 
 
 
 
 
Stem cells have been identified in a variety of tissues including the small 
intestine, colon, epidermis, bone marrow, fat, amniotic fluid, liver, and muscles (Barker 
et al., 2007; Hamid et al., 2017; Miyajima, Tanaka, and Itoh, 2014; Pang, Ibrahim, 
Bulstrode, and Ferretti, 2017; Wang, Dumont, and Rudnicki, 2014). Figure 4 illustrates a 
variety of applications in which iPSCs are associated with research and their potential to 
impact clinical medicine (Kumar, Anand, and Kues, 2016). Researchers have been 
investigating migration and differentiation of endogenous neural stem cells after complex 
spinal cord injuries affecting the nervous, vascular and immune systems (Liu et al., 
2017). In addition, human fetal neural stem cells (NSC) generated from human fetal 
tissue have been used as cell replacement therapy for the treatment of neurodegenerative 
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disorders such as Huntington's disease (Martin-Ibanez et al., 2017). Neural stem cells are 
being used in conjunction with nanomedicine to contribute to adult neurogenesis and 
various therapeutic approaches. Nanoparticle drug delivery systems stimulate 
neurogenesis which has been shown to increase memory and motor functions in patients 
affected by neurodegenerative diseases (Carradori, Eyer, Saulnier, Preat, and Rieux, 
2017). Similarly, NSCs have proven promising as a clinical therapeutic approach to slow 
progression of the neurodegenerative disorder amyotrophic lateral sclerosis (ALS) 
(Czarzasta et al., 2017). The translational potential of iPSCs for clinical neurology is very 
important due to the imminent global health burden associated with the prevalence of 
neurodegenerative diseases which is said to increase in the coming decades (Devine & 
Patani, 2016).  
 
A summary of information regarding current regenerative medicine trials using 
stem cell therapies is reviewed in “Stem Cell Therapies in Clinical Trials: Progress and 
Challenges” published in 2015 in the peer-reviewed scientific research journal Cell by 
Alan Trounson and Courtney McDonald (Trounson & McDonald, 2015). Similarly, the 
paper “Pluripotent Stem Cells Progressing to The Clinic” published in the peer-reviewed 
scientific research journal Nature by Alan Trounson and Natalie D. DeWitt is an 
excellent source of additional information regarding current cell therapies and clinical 
trials (Trounson & Dewitt, 2015). 
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Exogenous Genome Engineering 
The groundbreaking CRISPR/CRISPR-associated protein 9 (CRISPR/Cas9) technology 
recently became a successful approach to modify genes via exogenous gene editing using 
modified clustered regularly interspaced short palindromic repeats (Cong, 2017). This 
versatile platform uses RNA-guided genome engineering to modify cellular functions 
(Cong, 2017). This unprecedented technology avoids the previously labor-intensive work 
that was required to attempt genome editing. The advent of CRISPR/Cas9 has changed 
how scientific research is conducted, especially in the realm of stem cells (Cong, 2017). 
This technology has the potential to move beyond translational medicine as this approach 
allows in vivo genome engineering. Therefore, human diseases can be further evaluated 
and the potential to change the face of clinical treatments exists. The RNA-mediated 
nucleic acid cleavage is highly-specific and allows unprecedented editing of genomic loci 
in eukaryotic cells (Doudna & Charpentier, 2014). Impressive manipulation is possible 
because this detailed modality allows integration of RNA and protein components. 
Targeted design of genetically modified cells of specific disease phenotypes is now 
possible as this technology allows precise genetic modifications (Kumar, Anand, and 
Kues, 2016). Figure 5 displays different strategies of the CRISPR-Cas9 genome 
engineering tool (Doudna & Charpentier, 2014). This is a very exciting topic that will be 
monumental in future discoveries and is sure to result in successful innovative clinical 
applications.   
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Figure 5. Genome Engineering with CRISPR-Cas9. The versatile platform of stem 
cells has great potential to move beyond translational medicine since the groundbreaking  
CRISPR/CRISPR-associated protein 9 (CRISPR/Cas9) technology became a successful 
approach to modifying genes. It is possible to alter cellular functions using exogenous 
gene editing by in vivo genome engineering by way of RNA-guided modification assisted 
by clustered regularly interspaced short palindromic repeats (CRISPR). This highly 
specific and detailed modality facilitates integration of RNA and protein components to 
allow precise genetic modifications. Strategies of the CRISPR-Cas9 genome engineering 
tool include (A) double-stranded DNA breaks into genomic loci and suggests endogenous 
cellular DNA repair machinery to accomplish homology-directed repair (HDR) or non-
homologous end joining (NHEJ). Additionally, Cas9 is capable of functioning as a 
nickase which can be engineered to contain an inactivating mutation (B). Coordination of 
double strand break is possible by Cas9 nickase. Finally, Cas9 can be engineered to act as 
an RNA-guided DNA binding protein which can contain inactivating mutations such that 
both strands are affected (C). Therefore, this results in Cas9 mediated transcriptional 
down-regulation or activation if fused to activator or repressor domains. This allows Cas9 
to successfully interact with DNA modification domains resulting in epigenetic changes 
to genomic DNA. Image from (Doudna & Charpentier, 2014).  
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Limitations  
Human-induced pluripotent stem cells have promising widespread clinical potential; 
however, meticulous safety testing is crucial. Due to limitation of the murine model, 
studies must include long-term animal study of rodents as well as larger mammalian 
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models for sufficient pre-clinical assessment of potential cell therapy obstacles and risks. 
(Kumar, Anand, and Kues, 2016). Future research should address the most efficacious 
strategy to minimize or overcome risks associated with iPS cell-based therapies. 
Investigation must include review of long-term stability of the transplanted cells, 
functional integration into the host tissue, and freedom from undifferentiated iPSCs.  
  
 A variety of potential risks associated with iPS cell based therapies exist (Figure 
6) (Kumar, Anand, and Kues, 2016). Research has revealed direct effects or off-target 
effects associated with reprogramming may include viral integration into the genome or 
teratoma formation (Kumar, Anand, and Kues, 2016). Similarly, use of viral vectors 
includes a risk such as insertional mutagenesis which may result in upregulation or down 
regulation of neighboring genes. Therefore, subjects could be at risk for detrimental 
overexpression of oncogenes suggested by evidence of cancer. In addition, 
reprogramming may result in integration-induced mutagenesis or the aggregation of pre-
existing mutations (Kumar, Anand, and Kues, 2016). Additionally, it is unknown if 
introduced cells will be able to produce the desired product or if they will be able to be 
correctly regulated (Gurdon & Melton, 2008). Genome alteration due to viral insertion is 
a great concern as well as genome integrity. Issues such as altered expression of 
endogenous mutations can cause harm or disease (Kumar, Anand, and Kues, 2016). 
Substantial risks burden stem cell research, yet improved knowledge and understanding 
of this technology will move regenerative and personalized medicine toward safety and 
emerging clinical medicine.  
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Figure 6. iPS Cell-Based Therapies & Associated Risks. Though iPSCs promise 
widespread clinical potential and future monumental discoveries, limitations and 
associated risks have been revealed.  Research has revealed direct effects or off-target 
effects associated with reprogramming therefore, a variety of potential risks associated 
with iPSC based therapies exist. A plethora of potential cell therapy obstacles and risks 
include but are not limited to altered expression of genes, integration-induced 
mutagenesis or insertional mutagenesis. Image from (Kumar, Anand, and Kues, 2016). 
 
 
CONCLUSION 
Scientific research has incessantly been on a quest to better understand 
developmental biology and the complexity of life. Diligent investigators in pursuit of 
questions concerning organismal growth and development discovered a uniquely 
complex cell type which was defined as a stem cell. These cells have since been 
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characterized as cells capable of indefinite proliferation as well as the ability to produce 
differentiated cells. This finding immediately captivated the attention of the scientific 
research community. The potential benefit to medicine and biology has intrigued medical 
professionals as well as the biotechnology and pharmaceutical industries for several 
decades. Research entities have relentlessly studied these cells and later discovery and 
development of iPSC technology promise unprecedented opportunities for scientific 
study and regenerative medicine (Li & Belmonte, 2017). 
 
Disease, injury and disorders have become global burdens such that health care 
and efficacious treatments are becoming an increasing public health concern. Many 
treatment strategies are minimally beneficial, expensive and time-consuming. A network 
of industries are working together to overcome the present barriers to apply this 
innovative technology to regenerative medicine and clinical accessibility. Health 
concerns such as wound healing, cancer, central nervous system disease, neuropsychiatric 
disorders and osteoarthritis have been impacted by iPSCs. (Hung, Khan, Lo, Hewitt, and 
Wong, 2017; Jaferian, Soleymaninejad, Negahdari, and Eatemadi, 2017; Pang, Ibrahim, 
Bulstrode, and Ferretti, 2017; Young-Pearse & Morrow, 2016; Yu et al., 2016). 
Continued research will further uncover the complex network regulating the state of 
pluripotency and thus the promise of remarkable discoveries. Carefully considering the 
limitations of the technology, the capacity to investigate, define, diagnose, treat and cure 
health issues is sure to overwhelmingly increase in the years to come.
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